Kristof brings more than 20 years of experience in small molecule drug discovery in Pharma and Biotech, with a proven track record of leadership, entrepreneurial thinking and scientific innovation.
Throughout his career, Kristof has worked on a range of therapeutic target classes across disease areas such as immunology, oncology, infectious and gastrointestinal diseases.
His expertise encompasses the fields of medicinal chemistry, complemented by practical and managerial experience in managing both single projects and discovery portfolios.
Prior to joining Ermium he held key positions at ProDigest and J&J, including Head of Medicinal Chemistry at Tibotec and Director Emerging Sciences and Innovation at Janssen. He contributed to several products advancing to clinical trials and successfully established and led multiple strategic partnerships with academia, CROs and Biotech companies.
He received his PhD in organic chemistry from the KU Leuven, where he worked with Prof. G. Hoornaert on non-peptide Substance P-antagonists.
Management team
Scientific Advisor
Director of Research 1st class at the CNRS, directing the multidisciplinary Chemistry & Biology, Modeling & Immunology for Therapy (CBMIT) team within the CNRS and the Université de Paris
Board Of Directors
Scientific Advisory Board
Director of Research 1st class at the CNRS, directing the multidisciplinary Chemistry & Biology, Modeling & Immunology for Therapy (CBMIT) team within the CNRS and the Université de Paris
Chief Executive Officer of the Institute for Research in Immunology and Cancer at the University of Montréal
Professor of Target and Systems Biochemistry at the Faculty of Science of the Vrije Universiteit Amsterdam
